Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.34 |
| ▸ | NPY4R | P50391 | 4/20 | 0.34 |
| ▸ | NPY1R | P25929 | 3/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 2/20 | 0.33 |
| ▸ | FNTB | P49356 | 2/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | FURIN | P09958 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23420959 | 0.92 | FAP (0.37) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL20887736 | 0.92 | FAP (0.37) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL27421373 | 0.91 | FAP (0.36) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL29308956 | 0.89 | NPY5R (0.40) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL29647873 | 0.89 | FAP (0.38) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22134344 | 0.88 | C3AR1 (0.40) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL19257624 | 0.88 | NPY5R (0.38) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL13078356 | 0.88 | NPY5R (0.38) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL23256221 | 0.88 | NPY5R (0.38) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL2801888 | 0.88 | C3AR1 (0.40) | FAPNPY5RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | NOVARTIS AG (CH) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | CD2, CD2BP2, CD22 | FAP 550/4885NPY5R 4544/4885NPY4R 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.